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Abstract Interactions between environment and genetics
may contribute to multiple sclerosis (MS) development.
We investigated whether the previously observed interac-
tion between smoking and HLA genotype in the Swedish
population could be replicated, refined and extended to
include other populations. We used six independent case–
control studies from five different countries (Sweden,
Denmark, Norway, Serbia, United States). A pooled anal-
ysis was performed for replication of previous observations
(7190 cases, 8876 controls). Refined detailed analyses were
carried out by combining the genetically similar popula-
tions from the Nordic studies (6265 cases, 8401 controls).
In both the pooled analyses and in the combined Nordic
material, interactions were observed between HLA-
DRB*15 and absence of HLA-A*02 and between smoking
and each of the genetic risk factors. Two way interactions
were observed between each combination of the three
variables, invariant over categories of the third. Further,
there was also a three way interaction between the risk
factors. The difference in MS risk between the extremes
was considerable; smokers carrying HLA-DRB1*15 and
lacking HLA-A*02 had a 13-fold increased risk compared
with never smokers without these genetic risk factors (OR
12.7, 95% CI 10.8–14.9). The risk of MS associated with
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HLA genotypes is strongly influenced by smoking status
and vice versa. Since the function of HLA molecules is to
present peptide antigens to T cells, the demonstrated
interactions strongly suggest that smoking alters MS risk
through actions on adaptive immunity.
Keywords Multiple sclerosis  Smoking  HLA 
Gene–environment interaction
Introduction
Multiple sclerosis (MS) arises from a combination of a
complex genetic predisposition and environmental factors.
The strongest genetic associations with MS are located
within the human leukocyte antigen (HLA) complex [1, 2]
whereas genetic regions outside the HLA complex that
influence disease susceptibility have a smaller impact on
the disease risk [3, 4]. Well-established environmental
factors associated with MS risk are Epstein–Barr virus
(EBV) infection [5, 6], vitamin D status [7], sun exposure
habits [8], adolescent body mass index [9, 10], and
smoking [11]. Interactions between environmental factors
and genetics are likely to be involved in the etiology of
MS. Based on the Swedish project Epidemiological
Investigation of Multiple Sclerosis (EIMS), an interaction
between smoking and HLA complex genes regarding risk
of MS was reported in 2011 [12]. Smoking increased the
risk of MS by a factor of 1.5 among those without HLA
associated genetic risk and a combination of the genetic
risk factors presence of HLA-DRB*15 and absence of
HLA-A*02 increased the risk by a factor of 5.0 among
non-smokers. However, among smokers with both genetic
risk factors, there was a 15-fold increased risk, compared
with non-smokers with neither of the genetic risk factors
[12]. Using six independent case–control studies from five
different countries, we aimed to investigate whether the
finding of an interaction between smoking and HLA
genotype could be replicated, refined and extended to
include other populations.
Methods
Study design and data collection
For each study a more detailed description of study design
and data collection is presented in supplementary table 1,
and a flow chart presenting the falling-off in each study is
presented in Table 1.
Swedish studies
The first Swedish study was based on EIMS which is an
ongoing population-based case–control study, comprising
the Swedish general population aged 16–70 years. Incident
cases of MS were recruited from neurology clinics,
including all university hospitals in Sweden. All cases
fulfilled the McDonald criteria [13]. For each case, two
controls were randomly selected from the national popu-
lation register, frequency matched for the case’s age in
5-year age strata, gender and residential area. Ethical
approval was obtained from the Regional Ethical Review
Board at Karolinska Institutet. Our previous study pre-
senting an interaction between HLA genotype and smoking
based on EIMS used study participants recruited between
April 2005 and October 2008 [10]. The EIMS replication
analysis was restricted to include participants of Nordic
origin (Sweden, Norway, or Denmark) recruited between
November 2008 and December 2013. When the Nordic
studies were combined into one dataset for more detailed
analysis, we included EIMS participants of Nordic origin
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recruited between April 2005 and December 2013. The
replication analysis comprised 763 cases and 1037 con-
trols, whereas 1308 cases and 1858 controls were included
in the combined Nordic analysis (Table 1).
The second Swedish study was Genes and Environment
in Multiple Sclerosis (GEMS) in which prevalent cases,
distinct from those in EIMS, were identified from the
Swedish National MS-registry [14] and controls were
randomly selected from the national population register
matched for age, gender, and residential area at the time of
disease onset. Ethical approval was obtained from the
relevant ethics committee. All cases fulfilled the McDonald
criteria [13]. The study participants were recruited between
November 2009 and November 2011. The part of GEMS
used in this report comprised 3272 prevalent cases and
2382 matched controls (Table 1).
Danish study
Patients fulfilling theMcDonald criteria were recruited from
Neurology units in Danish hospitals between October 2009
and December 2014. The control group comprised healthy
white Danish blood donors residing in the area of Copen-
hagen. The controls werematched to the cases by gender and
age in 5-year age strata when included in the present study.
Informed consent was obtained from all participants and the
study was approved by the local Ethics Committee. The part
of the Danish study used in this report comprised 1474
prevalent cases and 3469 controls (Table 1).
Norwegian study
The Norwegian cases were recruited from the Oslo MS Reg-
istry [15] and the controls were recruited from the Norwegian
Bone Marrow Donor Registry. The cases were diagnosed in
accordance with the Poser and/or McDonald criteria [16, 17]
and informed written consent was obtained from all partici-
pants. The study was approved by the Regional Committee for
Medical and Health Research Ethics South East, Norway. The
controls were matched to the cases by gender and age in 5-year
age strata when included in the present study. The part of the
Norwegian study used in this report comprised 211 prevalent
cases and 692 controls (Table 1).
Serbian study
Cases to the Serbian study were recruited at the Military
Medical Academy. All patients fulfilled the McDonald
criteria. Controls comprised of volunteers from employees
of the Military Medical Academy and from the community.
The recruitment of cases and controls took place during
2009 and 2010. Ethical approval was obtained by Ethical
Committee of Military Medical Academy. In total, 457
cases and 505 controls from the Serbian study was included
in the analysis.
American study
The American case–control study is based on prevalent
cases identified among members of Kaiser Permanente
Medical Care Plan, Northern California Region (KPNC)
using electronic medical records. Controls were randomly
selected from KPNC members and were individually
matched to cases on gender, birth date, race/ethnicity, and
zip code of the case residence. The study protocol was
approved by the Institutional Review Boards of the KP
Division of Research and the University of California,
Berkeley. The part of the KPNC study used in this report
comprised 1013 prevalent cases and 794 controls.
Table 1 Flow chart, Nordic studies
Study Included in
the study
Data on smoking, birth year,
and gender. No overlap
EIMS/GEMS
Nordic
origin
Past smokers
excluded
HLA genotype available.
Dataset for analysis
EIMS
Cases 2488 2488 2027 1569 1308
Controls 5433 5433 4243 3379 1858
GEMS
Cases 6156 6085 5520 4264 3272
Controls 5408 5357 4568 3762 2382
Danish study
Cases 2048 2048 1832 1520 1474
Controls 4546 4541 4277 3618 3469
Norwegian study
Cases 332 316 316 278 211
Controls 773 756 748 702 692
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Definition of smoking habits
For each case in all studies but the Serbian and American
studies, the time of the initial appearance of MS symptoms
was used as an estimate of the disease onset, and the year in
which this occurred was defined as the index year. The
corresponding controls were given the same index year.
Subjects who smoked regularly during the index year were
defined as smokers whereas those who had never smoked
before or during the index year were defined as never
smokers. We have previously demonstrated that the
increased risk of developing MS associated with smoking
slowly abates after smoking cessation. A decade after
stopping smoking, there is no longer an association
between smoking and MS risk [11]. Therefore, subjects
who had stopped smoking before the index year were
excluded. In the Serbian and American study, less detailed
data on smoking habits was available and smoking was
defined as ever- or never-smoking at the time of inclusion
in the study.
Genotyping and definitions of genetic risk factors
Subjects in all studies were genotyped for HLA-DRB1*15
and HLA-A*02 alleles. Detailed information regarding
genotyping in each study is presented in supplementary
table 1. The HLA-DRB1*15 allele is associated with an
increased risk of developing MS with an OR around 3, and
the subjects were classified according to the carriage of any
HLA-DRB1*15 allele versus no carriage. The HLA-A*02
allele has protective association to MS. Absence of HLA-
A*02 is thus a risk factor of developing the disease, and the
participants were classified according to no carriage of any
HLA-A*02 allele versus carriage.
Statistical analysis
Subjects with different genotypes and smoking habits were
compared with regard to MS risk, by calculating odds
ratios (OR) with 95% confidence intervals (CI) using
logistic regression models. When controls are frequency
matched to cases, the matching variables should be inclu-
ded in an unconditional logistic model, whereas conditional
logistic regression, in which each matched set forms a
stratum, should be used when controls are individually
matched to cases. However, losses may be substantial when
data contain incomplete matched sets. Data from an indi-
vidual matched case–control study may also be analyzed
with unconditional logistic regression as long as the vari-
ables used to form the match are included in the model.
In all studies but the Serbian and American studies, we
performed both matched and unmatched analyses of the
data. However, only the results from the unmatched
analyses are presented since these were in close agreement
with those from the matched analyses but had higher pre-
cision in terms of more narrow confidence intervals. The
Serbian data was analyzed using only unconditional
logistic regression whereas conditional logistic regression
was used when analyzing the American study.
We investigated the gene–gene interaction between
HLA-DRB1*15 and absence of HLA-A*02 as well as the
interactions between each of these genetic risk factors and
smoking. The potential interactions were analysed using
departure from additivity of effects [18, 19] and evaluated
by calculating AP (attributable proportion due to interac-
tion), RERI (relative excess rate due to interaction), and SI
(synergy index) together with 95% confidence intervals,
using the delta method [20]. We also studied the total
three-way interaction between HLA-DRB1*15, absence of
HLA-A*02, and smoking with regard to MS risk, com-
paring the joint effect of the three risk factors to the situ-
ation when each one acts separately, using the total relative
excess risk due to interaction (TotRERI3), the total
attributable proportion (TotAP3) and the total synergy
index (TotSI3);
TotRERI3 ðX1; X2; X3Þ ¼ ðRRX1þX2þX3þ  RRX1X2X3Þ
 ðRRX1þX2X3  RRX1X2X3Þ
 ðRRX1X2þX3  RRX1X2X3Þ
 ðRRX1X2X3þ  RRX1X2X3Þ
¼ RRX1þX2þX3þ  RRX1þX2X3
 RRX1X2þX3  RRX1X2X3þ þ 2
TotAP3 ðX1;X2;X3Þ ¼ TotRERI3 ðX1; X2; X3Þ
RRX1þX2þX3þ
TotSI3 ðX1; X2; X3Þ
¼ ðRRX1þX2þX3þ  1ÞðRRX1þX2X3  1Þ þ ðRRX1X2þX3  1Þ þ ðRRX1X2X3þ  1Þ
where Xi?, Xi- denote the presence (Xi = 1) or absence
(Xi = 0) of Xi, i = 1, 2, 3, and RR the relative risk for the
development of the disease, given the combination of the
presence or absence of the risk factors X1, X2, … X3, as
compared to their absence [21]. These measures of inter-
action between the three factors combine all two-way
interactions, when the 3rd risk factor is absent, as well as
the three-way interaction, hence called total interaction.
We also calculated measures of the three-way interaction
where the influence from the possible two-way interactions
between the three factors was removed (denoted RERI3,
AP3 and SI3) [Katsoulis M and Bamia C. Moving from
two- to multi-way interactions among binary factors on the
additive scale. Under revision in Am J Epidemiol].
When the results from all six studies were pooled
together, study specific results (adjusted for age and gen-
der) were pooled together by utilising a model allowing for
A. K. Hedstro¨m et al.
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random effects. When the Nordic studies were combined
into one, the analyses were adjusted for age, gender and
study.
In EIMS and GEMS, the interaction analyses were
further adjusted for a large number of potential con-
founding variables described in supplementary table 2.
Adjustment for these factors had minor influence on the
results. The analyses were conducted using Statistical
Analysis System (SAS) version 9.2 and Stata Statistical
Software, release 11 (StataCorp. 2009, StataCorp LP).
Results
The increased MS risk associated with smoking was similar
in all studies. HLA-DRB1*15 increased the risk of MS in
all studies, whereas HLA-A*02 was associated with a
decreased MS risk in all studies but the Serbian study
(supplementary table 3). In the pooled analyses there was
an interaction between HLA-DRB*15 and absence of
HLA-A*02 and between smoking and each of the genetic
risk factors (Table 2). The previously reported interaction
between HLA-DRB1*15 and HLA-A*02 [12] was repli-
cated in all studies, except for the Serbian study. An
interaction between smoking and HLA-DRB1*15 was
observed in all studies. With regard to the interaction
between smoking and absence of HLA-A*02, an interac-
tion was observed only in the Nordic studies. The results
from each of the separate studies are presented in supple-
mentary table 4 whereas the main effects of the HLA
genotypes and smoking for each cohort are presented in
Table 3.
By combining the Nordic datasets (6265 cases and 8401
controls), we show that interactions take place between
both HLA-DRB1*15 and HLA-A*02 regardless of smok-
ing status (Table 4A), between HLA-A*02 and smoking
regardless of HLA-DRB1*15 status (Table 4B), and
between HLA-DRB1*15 and smoking regardless of HLA-
A*02 status (Table 4C). In all Nordic studies, an overall
interaction was observed between these three risk factors
(Table 5). However, when the influence from two way
interactions was removed, the remaining three way
Table 2 Replication and extension of previous results
DR15? A2- ca/coa OR (95% CI)b p AP
OR with 95% CI of developing MS for subjects categorized by HLA-DRB1*15 and HLA-A*02. Attributable proportion due to interaction
between HLA-DRB1*15 and HLA-A*02
- - 1232/3354 1.0 (–) 1.0 (–)
- ? 1734/2881 1.6 (1.4–1.8) \0.0001
? - 1864/1457 3.6 (3.2–4.0) \0.0001
? ? 2360/1184 5.7 (5.2–6.3) \0.0001 0.34 (0.29–0.39), p = 0.0004
A2- Smoking ca/coa OR (95% CI)c p AP
OR with 95% CI of developing MS for subjects categorized by HLA-A*02 and smoking. Attributable proportion due to interaction between
HLA-A*02 and smoking
- - 1517/3181 1.0 (-)
- ? 1579/1630 3.2 (3.6–4.0) \0.0001
? - 2116/2764 1.8 (1.5–2.1) \0.0001
? ? 1978/1301 5.4 (4.4–6.6) \0.0001 0.21 (0.16–0.27), p\ 0.0001
DR15? Smoking ca/coa OR (95% CI)d p AP
OR with 95% CI of developing MS for subjects categorized by HLA-DRB1*15 and smoking. Attributable proportion due to interaction between
HLA-DRB1*15 and smoking
- - 1435/4164 1.0 (–)
- ? 1531/2071 3.3 (2.7–3.9) \0.0001
? - 2198/1781 3.6 (3.0–4.3) \0.0001
? ? 2026/860 10.4 (8.5–12.8) \0.0001 0.35 (0.30–0.40), p\ 0.0001
All studies pooled together
a Number of exposed cases and controls
b Adjusted for age, gender, and smoking
c Adjusted for age, gender, and HLA-DRB1*15
d Adjusted for age, gender, and HLA-A*02
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interaction was only significant in the EIMS study, and
marginally significant in the combined Nordic study
(Table 6).
All analyses were adjusted for age and gender. Smoking
has previously been found to correlate with exposure to
passive smoking, snuff use, and to a minor extent, alcohol
consumption. Therefore, we also present the results in
EIMS and GEMS with adjustment for these factors. We
further adjusted for an additional number of potential
confounding factors including adolescent body mass index,
sun exposure habits during the last 5 years, a history of
mononucleosis, educational level, and socioeconomic sta-
tus. However, all potential confounding variables only had
minor influence on the results and were not retained when
the Nordic studies were combined into one.
Discussion
The previously reported interaction between smoking and
HLA genotype was replicated and extended to include
other populations. By combining the genetically similar
populations from the Nordic studies we had the opportunity
to study the interaction between smoking, HLA-DRB1*15
and absence of HLA-A*02 in detail. Two way interactions
were observed between each combination of the three
variables, invariant over categories of the third. Further,
there was also a three way interaction between the risk
factors in the EIMS study, and a marginally significant
three way interaction for all the Nordic studies combined.
The difference in MS risk between the extremes was
considerable; smokers carrying HLA-DRB1*15 and lack-
ing HLA-A*02 had a 13-fold increased risk compared with
never smokers without these genetic risk factors (OR 12.7,
95% CI 10.8–14.9).
An interaction between smoking and absence of HLA-
A*02 was observed only in the Nordic studies. No inter-
action between smoking and absence of HLA-A*02 was
observed in the Serbian or American cohort. This could be
due to chance, differences in life style habits or in genetic
background. Notably, the HLA-A*02 protective associa-
tion to MS vary considerably between different populations
[3, 22].
Since use of oral tobacco in the form of moist snuff is
not associated with increased risk of MS [23], the critical
effects of smoking may be caused by irritation in the lungs.
A similar interaction has been observed between passive
smoking and the same MS risk HLA genes with regard to
MS risk [24]. Thus, lung-irritation displays a considerably
higher association with MS among people with a genetic
susceptibility to the disease. In addition, non-specific lung-
irritation due to organic solvents is also associated with an
increased risk of MS as demonstrated in a meta-analysis
[25].
There are several potential mechanisms that can be
involved in a casual role of smoking. Smoke-induced lung-
irritation causes increased pro-inflammatory cell activation
and induces post-translational modifications of proteins in
the lungs [26–28]. Altered self through peptide modifica-
tions may lead to a bypass of thymic tolerance and trig-
gering of autoimmune disease, as has been experimentally
demonstrated for myelin oligodendrocyte glycoprotein
[29]. Interestingly, the lungs contribute to the T cell acti-
vation and migration that are required for experimental
autoimmune encephalomyelitis (EAE) initiation [30].
Potentially autoaggressive effector and memory cells are
also present and available for triggering in the lungs. In
EAE studies, these cells strongly proliferate after local
stimulation of the lungs and, after assuming migratory
properties, enter the central nervous system (CNS) and
induce autoimmune responses [30]. Any CNS autoreactive
T cells present in the lung could thus be activated by the
proinflammatory action of smoking.
The specific interactions may shed light on potential
disease mechanisms for MS. Preferences in peptide
binding by allelic variants of class II molecules are likely
Table 3 Two way interactions on the additive scale between HLA-DRB1*15 and absence of HLA-A*02, between absence of HLA-A*02 and
smoking, and between HLA-DRB1*15 and smoking
DR15 A2- Smoking APa APb APc APd APe APf
x x 0.4 (0.2–0.5) 0.2 (0.04–0.3) 0.3 (0.1–0.4) 0.5 (0.2–0.7) -0.3 (-1 to 0.4) 0.5 (0.3–0.7)
x x 0.3 (0.1–0.5) 0.2 (0.008–0.3) 0.2 (0.005–0.3) 0.3 (0.0–0.7) 0.2 (-0.09 to 0.6) 0.0 (-0.3 to 0.3)
x x 0.3 (0.08–0.4) 0.2 (0.06–0.3) 0.4 (0.3–0.5) 0.3 (0.05–0.6) 0.4 (0.2–0.7) 0.4 (0.1–0.6)
Attributable proportion due to interaction with 95% CI
a EIMS, study
b GEMS
c Danish study
d Norwegian study
e Serbian study
f American study
A. K. Hedstro¨m et al.
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Table 4 Combined study using participants of Nordic origin
DR15? A2- ca/coa OR (95% CI)b p AP
A. OR with 95% CI of developing MS for subjects categorized by HLA-DRB1*15 and HLA-A*02, in total and stratified by smoking status.
Attributable proportion due to interaction between HLA-DRB1*15 and HLA-A*02
Total
- - 991/3192 1.0 (–)
- ? 1428/2639 1.8 (1.6–1.9) \0.0001
? - 1732/1439 3.9 (3.5–4.3) \0.0001
? ? 2114/1131 6.1 (5.5–6.8) \0.0001 0.2 (0.1–0.4), p\ 0.0001
DR15? A2- ca/coa OR (95% CI)c p AP
Never smokers
- - 490/2163 1.0 (–)
- ? 749/1861 1.8 (1.5–2.0) \0.0001
? - 922/975 4.1 (3.6–4.7) \0.0001
? ? 1152/787 6.4 (5.6–7.3) \0.0001 0.2 (0.1–0.3), p\ 0.0001
DR15? A2- ca/coa OR (95% CI)c p AP
Current smokers
- - 501/1029 1.0 (–)
- ? 679/778 1.8 (1.5–2.1) \0.0001
? - 810/464 3.6 (3.1–4.2) \0.0001
? ? 962/344 5.8 (4.9–6.8) \0.0001 0.2 (0.1–0.4), p\ 0.0001
A2- Smoking ca/coa OR (95% CI)d p AP
B. OR with 95% CI of developing MS for subjects categorized by HLA-A*02 and smoking, in total and stratified by HLA-DRB1*15 status.
Attributable proportion due to interaction between HLA-A*02 and smoking
Total
- - 1412/3138 1.0 (–)
- ? 1311/1493 2.0 (1.8–2.2) \0.0001
? - 1901/2648 1.6 (1.5–1.8) \0.0001
? ? 1641/1122 3.5 (3.1–3.9) \0.0001 0.2 (0.1–0.3), p\ 0.0001
A2- Smoking ca/coa OR (95% CI)c p AP
HLA-DRB1*15 negative
- - 490/2163 1.0 (–)
- ? 501/1029 2.1 (1.8–2.5) \0.0001
? - 749/1861 1.8 (1.5–2.0) \0.0001
? ? 679/778 3.8 (3.3–4.4) \0.0001 0.2 (0.1–0.3), p\ 0.0001
A2- Smoking ca/coa OR (95% CI)c p AP
HLA-DRB1*15 positive
- - 922/975 1.0 (–)
- ? 810/464 1.9 (1.6–2.2) \0.0001
? - 1152/787 1.6 (1.4–1.8) \0.0001
? ? 962/344 3.1 (2.7–3.7) \0.0001 0.2 (0.08–0.3), p = 0.002
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to be critical for the HLA class II influences on
autoimmune diseases [31]. The interaction between
smoking and HLA genotype with regard to MS risk is
consistent with class II allele specific recognition of
particular altered self peptides in the lungs, with ensuing
organ specific inflammatory disease depending on pref-
erential peptide binding by allelic variants of class II
molecules. Similarly, carriage of the shared epitope,
comprising HLA-DRB1*04, interacts with smoking to
increase the risk of rheumatoid arthritis [32]. We thus
hypothesize that smoking may contribute to the activation
of autoaggressive T cells in the lungs and subsequently
lead to MS in people with a genetic susceptibility to the
disease. Interpretation of the protective association of
HLA-A*02 in MS is more challenging. A role for CD8?
T cells is supported by histochemical studies of MS brain
lesions where CD8? T cells dominate over CD4? T
cells [33]. Class I molecules present antigen to CD8? T
cells which can be cytotoxic, but also convey suppressor
functions through production of molecules such as TGF b
[34]. Class I allele specific suppression mediated by
CD8? cells and TGF beta has been demonstrated in EAE
[35–37]. However, further research on CD8 ? cells in
relation to allelic influences is strongly warranted.
Table 4 continued
DR15? Smoking ca/coa OR (95% CI)e p AP
C. OR with 95% CI of developing MS for subjects categorized by HLA-DRB1*15 and smoking, in total and stratified by HLA-A*02 status.
Attributable proportion due to interaction between HLA-DRB1*15 and smoking
Total
- - 1239/4024 1.0 (–) –
? ? 1180/1807 2.1 (2.0–2.4) \0.0001
? - 2074/1762 3.8 (3.5-4.2) \0.0001
? ? 1772/808 7.4 (6.7-8.3) \0.0001 0.3 (0.26–0.4), p\ 0001
DR15? Smoking ca/coa OR (95% CI)c p AP
HLA-A*02 positive
- - 490/2163 1.0 (–)
- ? 501/1029 2.1 (1.9–2.5) \0.0001
? - 922/975 4.1 (3.6–4.7) \0.0001
? ? 810/464 7.7 (6.6–8.9) \0.0001 0.3 (0.2–0.4), p\ 0.0001
DR15? Smoking ca/coa OR (95% CI)c p AP
HLA-A*02 negative
- - 749/1861 1.0 (–)
- ? 679/778 2.2 (1.9–2.5) \0.0001
? - 1152/787 3.6 (3.2–4.1) \0.0001
? ? 344/962 7.2 (6.2–8.4) \0.0001 0.3 (0.2–0.4), p\ 0.0001
a Number of exposed cases and controls
b Adjusted for age, gender, smoking, and study
c Adjusted for age, gender, and study
d Adjusted for age, gender, HLA-DRB1*15, and study
e Adjusted for age, gender, HLA-A*02, and study
Table 5 Combined two- and
three-way interaction on the
additive scale between HLA-
DRB1*15, absence of HLA-
A*02, and smoking
Study TotAP3 TotRERI3 TotSI3
EIMS 0.6 (0.4–0.7) 6.7 (3.0–10.3) 2.9 (1.9–4.4)
GEMS 0.3 (0.2–0.5) 3.5 (1.3–5.7) 1.6 (1.2–2.1)
Danish study 0.6 (0.5–0.7) 10.8 (6.5–15.0) 2.8 (2.1–3.7)
Norwegian study 0.7 (0.5–0.9) 12.6 (1.1–24.2) 3.5 (1.6–8.0)
Nordic studies combined 0.5 (0.46–0.61) 6.8 (5.0–8.5) 2.4 (2.0–2.8)
Total attributable proportion due to interaction, relative excess risk and synergy index due to interaction,
with 95% CI
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Approximately 20% of all MS cases in Sweden has been
estimated to be attributable to active or passive smoking,
whereas 41% of the cases among those carrying HLA-
DRB1*15 but lacking HLA-A*02 were attributable to
smoking [38]. From a public health perspective, the impact
of smoking and passive smoking on MS risk is thus con-
siderable and preventive measures in order to reduce
tobacco smoke exposure are therefore essential.
In all studies, information regarding smoking habits was
collected retrospectively. The EIMS study was designed as
a case–control study with incident cases in order to mini-
mize recall bias, whereas the other studies used prevalent
cases. The questionnaires in all Nordic studies contained a
wide range of questions regarding many potential envi-
ronmental risk factors and no section in the questionnaires
was given prime focus. Furthermore, in the Nordic studies
as well as in the American study, exposure information
from cases and controls was obtained in an identical way
from cases and controls.
A potential selection bias may arise when recruiting
cases and controls. Considering the structure of the public
health care system in Sweden, which provides equal free of
charge access to medical services for all citizens, it is likely
that almost all cases of MS are referred to neurological
units. However, some cases may not have been asked to
participate in EIMS due to the attending neurologists’ lack
of time. In GEMS and the Norwegian study, cases were
identified through MS registers in each country and these
registers may not have covered all prevalent cases. In the
Danish study, the majority of cases were randomly
recruited by neurologists from hospitals with MS Centers
in Denmark and the cases may not be representative for the
general MS population. However, the recruitment of cases
was probably not affected by smoking or HLA genotype.
In the Swedish studies, the problem of selection bias
was minimized by the population-based design and even
though there was a relatively high proportion of non-re-
sponders among the controls, this bias is probably modest
because the prevalence of life style factors, such as
smoking and alcohol consumption, among the controls was
consistent with that of the general population in similar
ages [39]. The distribution of socioeconomic status among
controls was also in line with that of the general population
[40].
Furthermore, there were no significant differences with
respect to age, gender, or smoking habits between those
who provided a blood sample and those who did not,
indicating that selection bias did not take place in this step.
We consider it unlikely that our main finding of an inter-
action between MS risk HLA genotypes and exposure to
smoking would be affected by bias to a large extent,
especially since such a bias would then depend on HLA
types.
In the Danish study, the control group comprised healthy
white Danish blood donors and in the Norwegian study,
controls were selected from the National Bone Marrow
Donor Registry. In these studies, a selection bias towards a
more than normally healthy group may therefore have
occurred. However, educational level and autoimmune co-
morbidity were similar among Norwegian cases and con-
trols, indicating that the groups were comparable with
regard to socioeconomic status and thus probably also
general [40]. The proportion of regular smokers among the
controls was similar to the frequency in the general Nor-
wegian population, arguing for that the controls were
representative with regard to lifestyle factors.
In conclusion, an interaction between smoking and
HLA-DRB1*15 was observed in all cohorts, whereas an
interaction between smoking and absence of HLA-A*02
was observed only in the Nordic cohorts. The combined
Nordic studies allowed detailed analyses of the interaction
between the three studied factors, and in addition to sig-
nificant two way interactions between each combination of
the three variables, invariant over categories of the third,
there was a significant three way interaction between
smoking, HLA-DRB1*15, and absence of HLA-A*02. We
hypothesize that smoke-induced lung-irritation may trigger
autoaggressive T cells in the lungs or post-translationally
modify peptides that are cross-reactive with CNS antigens,
promoting a CNS-directed autoaggressive immunity that
results in MS.
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